MIB1/Ki-67 labelling index can classify grade 2 breast cancer into two clinically distinct subgroups

Breast Cancer Research and Treatment

Volumn 127, Issue 3, 2011, Pages 591-599

  Aleskandarany, Mohammed A ^a,b   Rakha, Emad A ^c   MacMillan, R Douglas ^c   Powe, Desmond G ^c   Ellis, Ian O ^a,c   Green, Andrew R ^a  

^a UNIVERSITY OF NOTTINGHAM   (United Kingdom)

^b MENOUFIA UNIVERSITY   (Egypt)

^c NOTTINGHAM UNIVERSITY HOSPITALS NHS TRUST   (United Kingdom)

Author keywords

Breast carcinoma; Grade; Growth fraction; Immunohistochemistry; Ki67

Indexed keywords

KI 67 ANTIGEN; TAMOXIFEN;

ADULT; AGED; ARTICLE; BREAST CANCER; BREAST CARCINOMA; CANCER CLASSIFICATION; CANCER GRADING; CONTROLLED STUDY; DISEASE FREE INTERVAL; DISEASE FREE SURVIVAL; FEMALE; HUMAN; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; OVERALL SURVIVAL; PRIORITY JOURNAL; RETROSPECTIVE STUDY; TUMOR VOLUME;

ADOLESCENT; ADULT; AGED; BREAST NEOPLASMS; CELL CYCLE PROTEINS; FEMALE; FLUORESCENT ANTIBODY TECHNIQUE; GENE EXPRESSION PROFILING; HUMANS; KI-67 ANTIGEN; MIDDLE AGED; MULTIVARIATE ANALYSIS; NEOPLASM METASTASIS; PROGNOSIS; TUMOR MARKERS, BIOLOGICAL;

EID: 79958277115     PISSN: 01676806     EISSN: 15737217     Source Type: Journal    
DOI: 10.1007/s10549-010-1028-3     Document Type: Article

References (31)

1. I Soerjomataram MW Louwman JG Ribot JA Roukema JW Coebergh 2008 An overview of prognostic factors for long-term survivors of breast cancer Breast Cancer Res Treat 107 309 330 17377838 10.1007/s10549-007-9556-1 1:CAS:528:DC%2BD1cXht1Sgtrw%3D (Pubitemid 351172108)
2. H Pereira SE Pinder DM Sibbering MH Galea CW Elston RW Blamey JF Robertson IO Ellis 1995 Pathological prognostic factors in breast cancer. IV: should you be a typer or a grader? A comparative study of two histological prognostic features in operable breast carcinoma Histopathology 27 219 226 8522285 10.1111/j.1365-2559.1995.tb00213.x 1:STN:280:DyaK287gtVWhuw%3D%3D
3. LW Dalton DL Page WD Dupont 1994 Histologic grading of breast carcinoma. A reproducibility study Cancer 73 2765 2770 8194018 10.1002/1097-0142(19940601) 73:11<2765::AID-CNCR2820731119>3.0.CO;2-K 1:STN:280:DyaK2c3ltFOitA%3D%3D (Pubitemid 24166264)
4. HF Frierson Jr RA Wolber KW Berean DW Franquemont MJ Gaffey JC Boyd DC Wilbur 1995 Interobserver reproducibility of the Nottingham modification of the Bloom and Richardson histologic grading scheme for infiltrating ductal carcinoma Am J Clin Pathol 103 195 198 7856562
5. M Ignatiadis C Sotiriou 2008 Understanding the molecular basis of histologic grade Pathobiology 75 104 111 18544965 10.1159/000123848 1:STN:280:DC%2BD1czns1yisg%3D%3D (Pubitemid 351820728)
6. ML Whitfield LK George GD Grant CM Perou 2006 Common markers of proliferation Nat Rev Cancer 6 99 106 16491069 10.1038/nrc1802 1:CAS:528:DC%2BD28Xht1eit74%3D (Pubitemid 43361542)
7. CW Elston IO Ellis 1991 Pathological prognostic factors in breast cancer. I. The value of histological grade in breast cancer: experience from a large study with long-term follow-up Histopathology 19 403 410 1757079 10.1111/j.1365-2559.1991.tb00229.x 1:STN:280:DyaK38%2FpvVSltw%3D%3D
8. PA Hall DA Levison 1990 Review: assessment of cell proliferation in histological material J Clin Pathol 43 184 192 2185282 10.1136/jcp.43.3.184 1:STN:280:DyaK3c3jslaltA%3D%3D (Pubitemid 20087565)
9. JS Meyer C Alvarez C Milikowski N Olson I Russo J Russo A Glass BA Zehnbauer K Lister R Parwaresch 2005 Breast carcinoma malignancy grading by Bloom-Richardson system vs proliferation index: reproducibility of grade and advantages of proliferation index Mod Pathol 18 1067 1078 15920556 10.1038/modpathol.3800388 (Pubitemid 41224497)
10. J Lynch R Pattekar DM Barnes AM Hanby RS Camplejohn K Ryder CE Gillett 2002 Mitotic counts provide additional prognostic information in grade II mammary carcinoma J Pathol 196 275 279 11857489 10.1002/path.1045 1:STN:280:DC%2BD387ktFOruw%3D%3D (Pubitemid 34189415)
11. B Haibe-Kains C Desmedt F Piette M Buyse F Cardoso L Van't Veer M Piccart G Bontempi C Sotiriou 2008 Comparison of prognostic gene expression signatures for breast cancer BMC Genomics 9 394 18717985 10.1186/1471-2164-9-394
12. H Dai L vant Veer J Lamb YD He M Mao BM Fine R Bernards M van de Vijver P Deutsch A Sachs R Stoughton S Friend 2005 A cell proliferation signature is a marker of extremely poor outcome in a subpopulation of breast cancer patients 65 4059 4066 1:CAS:528:DC%2BD2MXktlSmsLc%3D
13. H Bonnefoi C Underhill R Iggo D Cameron 2009 Predictive signatures for chemotherapy sensitivity in breast cancer: are they ready for use in the clinic? Eur J Cancer 45 1733 1743 19477634 10.1016/j.ejca.2009.04.036 1:CAS:528:DC%2BD1MXnsV2lu7w%3D
14. P Wirapati C Sotiriou S Kunkel P Farmer S Pradervand B Haibe-Kains C Desmedt M Ignatiadis T Sengstag F Schutz DR Goldstein M Piccart M Delorenzi 2008 Meta-analysis of gene expression profiles in breast cancer: toward a unified understanding of breast cancer subtyping and prognosis signatures Breast Cancer Res 10 R65 18662380 10.1186/bcr2124
15. MC Cheang SK Chia D Voduc D Gao S Leung J Snider M Watson S Davies PS Bernard JS Parker CM Perou MJ Ellis TO Nielsen 2009 Ki67 index, HER2 status, and prognosis of patients with luminal B breast cancer J Natl Cancer Inst 101 736 750 19436038 10.1093/jnci/djp082 1:CAS:528:DC%2BD1MXmtlyit74%3D
16. C Sotiriou P Wirapati S Loi A Harris S Fox J Smeds H Nordgren P Farmer V Praz B Haibe-Kains C Desmedt D Larsimont F Cardoso H Peterse D Nuyten M Buyse MJ Van de Vijver J Bergh M Piccart M Delorenzi 2006 Gene expression profiling in breast cancer: understanding the molecular basis of histologic grade to improve prognosis J Natl Cancer Inst 98 262 272 16478745 10.1093/jnci/djj052 1:CAS:528:DC%2BD28Xhs1Skt74%3D (Pubitemid 43264710)
17. XJ Ma R Salunga S Dahiya W Wang E Carney V Durbecq A Harris P Goss C Sotiriou M Erlander D Sgroi 2008 A five-gene molecular grade index and HOXB13:IL17BR are complementary prognostic factors in early stage breast cancer Clin Cancer Res 14 2601 2608 18451222 10.1158/1078-0432.CCR-07-5026 1:CAS:528:DC%2BD1cXlsV2qsbs%3D
18. EA Rakha ME El-Sayed JS Reis-Filho IO Ellis 2008 Expression profiling technology: its contribution to our understanding of breast cancer Histopathology 52 67 81 18171418 10.1111/j.1365-2559.2007.02894.x 1:STN:280:DC%2BD1c%2FgsF2msA%3D%3D (Pubitemid 350265184)
19. M Srinivasan D Sedmak S Jewell 2002 Effect of fixatives and tissue processing on the content and integrity of nucleic acids Am J Pathol 161 1961 1971 12466110 10.1016/S0002-9440(10)64472-0 1:CAS:528:DC%2BD38Xpslemtbw%3D (Pubitemid 35434840)
20. LM McShane DG Altman W Sauerbrei SE Taube M Gion GM Clark 2005 REporting recommendations for tumor MARKer prognostic studies (REMARK) Nat Clin Pract Oncol 2 416 422 16130938 10.1038/ncponc0252 1:CAS:528:DC%2BD2MXps1CksLY%3D (Pubitemid 43115010)
21. Ellis IO et al (2005) Pathology reporting of breast disease: a joint document incorporating the third edition of the NHS Breast Screening Programme's Guidelines for pathology reporting in breast cancer screening and the second edition of the Royal College of Pathologists' Minimum dataset for breast cancer histopathology. NHS Cancer Screening Programmes; Royal College of Pathologists
22. DM Abd El-Rehim G Ball SE Pinder E Rakha C Paish JFR Robertson D Macmillan RW Blamey IO Ellis 2005 High-throughput protein expression analysis using tissue microarray technology of a large well-characterised series identifies biologically distinct classes of breast cancer confirming recent cDNA expression analyses Int J Cancer 116 340 350 15818618 10.1002/ijc.21004 1:CAS:528:DC%2BD2MXmtl2ktb0%3D (Pubitemid 40993329)
23. MA Aleskandarany AR Green EA Rakha RA Mohammed SE Elsheikh DG Powe EC Paish RD Macmillan S Chan SI Ahmed IO Ellis 2010 Growth fraction as a predictor of response to chemotherapy in node negative breast cancer Int J Cancer 126 7 1761 1769 19711345 1:CAS:528:DC%2BC3cXhtl2it70%3D
24. EA Rakha SE Elsheikh MA Aleskandarany HO Habashi AR Green DG Powe ME El-Sayed A Benhasouna JS Brunet LA Akslen AJ Evans R Blamey JS Reis-Filho WD Foulkes IO Ellis 2009 Triple-negative breast cancer: distinguishing between basal and nonbasal subtypes Clin Cancer Res 15 2302 2310 19318481 10.1158/1078-0432.CCR-08-2132 1:CAS:528:DC%2BD1MXjvVWltbs%3D
25. RL Camp M Dolled-Filhart DL Rimm 2004 X-Tile: a new bio-informatics tool for biomarker assessment and outcome-based cut-point optimization 10 7252 7259 1:CAS:528:DC%2BD2cXpsVKltbc%3D
26. PT Simpson JS Reis-Filho T Gale SR Lakhani 2005 Molecular evolution of breast cancer J Pathol 205 248 254 15641021 10.1002/path.1691 1:CAS:528:DC%2BD2MXhsFOgsrs%3D (Pubitemid 40227995)
27. CW Elston IO Ellis SE Pinder 1999 Pathological prognostic factors in breast cancer Crit Rev Oncol Hematol 31 209 223 10532196 10.1016/S1040-8428(99) 00034-7 1:STN:280:DC%2BD3c%2FgtFajtw%3D%3D (Pubitemid 29424143)
28. L Pusztai GN Hortobagyi 1998 High-dose chemotherapy: how resistant is breast cancer? Drug Resist Updat 1 62 72 17092798 10.1016/S1368-7646(98)80216-1 1:CAS:528:DyaK1MXisVCmsrw%3D
29. CW Elston IO Ellis 2002 Pathological prognostic factors in breast cancer. I. The value of histological grade in breast cancer: experience from a large study with long-term follow-up Histopathology 41 154 161 12405947 10.1046/j.1365-2559.2002.14691.x 1:STN:280:DC%2BD28%2Fks1Ohuw%3D%3D (Pubitemid 41713015)
30. V Le Doussal M Tubiana-Hulin S Friedman K Hacene F Spyratos M Brunet 1989 Prognostic value of histologic grade nuclear components of Scarff-Bloom- Richardson (SBR). An improved score modification based on a multivariate analysis of 1262 invasive ductal breast carcinomas Cancer 64 1914 1921 2551477 10.1002/1097-0142(19891101)64:9<1914::AID-CNCR2820640926>3.0.CO;2-G (Pubitemid 19267813)
31. JP Baak PJ van Diest FJ Voorhorst E van der Wall LV Beex JB Vermorken EA Janssen 2005 Prospective multicenter validation of the independent prognostic value of the mitotic activity index in lymph node-negative breast cancer patients younger than 55 years J Clin Oncol 23 5993 6001 16135467 10.1200/JCO.2005.05.511